MAIA Biotechnology, Inc.
MAIA NYSE· Pharmaceutical Preparations
Last close · Oct 23, 2026
$1.15
KIRA · Stoqly’s AI analyst, in plain words
- MAIA Biotechnology, Inc. lost $22.4M in fiscal 2025.
Market cap
$69.9M
P/E
—
Revenue
—
Net income
−$22.4M
Free cash flow
—
Operating margin
—
MAIA Biotechnology, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$22.4M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What MAIA Biotechnology, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 23, 2026
- Legal name
- MAIA Biotechnology, Inc.
- CIK
- 0001878313
MAIA Biotechnology, Inc. · MAIA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | $0.0M | $0.0M | $0.0M | — |
| Net income | −$12.6M | −$15.8M | −$19.8M | −$23.3M | −$22.4M |
| Diluted EPS | −$2.37 | −$1.75 | −$1.49 | −$1.05 | −$0.70 |
| Cash | |||||
| Cash from operations | −$4.1M | −$12.1M | −$13.1M | −$15.7M | −$18.8M |
| Share count change | — | 75.8% | 43.0% | 67.4% | 44.7% |
| Debt and strength | |||||
| Cash and short-term investments | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $9.2M | $8.5M | $0.5M | $3.6M | $2.4M |
| Current ratio | 5.0x | 3.6x | 1.5x | 2.7x | 1.7x |
| Interest coverage | −9.4x | −2,310.9x | −2,925.0x | −169,572.0x | — |
| Returns and quality | |||||
| Return on equity | −137.0% | −178.3% | −440.1% | −1,131.0% | −745.2% |
| Return on tangible equity | −136.2% | −190.6% | −4,140.9% | −639.8% | −942.6% |
| Piotroski F-score | — | — | 1 | 3 | — |
| Altman Z'' | −3.4 | −13.8 | −43.1 | −34.6 | −50.7 |
Insiders bought, 12 months
$1.0M
7 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
MAIA Biotechnology, Inc. · MAIA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.15 a share, the company is worth $69.9M.
Source: SEC EDGAR XBRL filings (CIK 0001878313). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.